The prespecified primary endpoints maximizing cross-trial comparability were alanine aminotransferase (ALT), triglycerides (TG), Homeostatic Model Assessment of Insulin resistance (HOMA-IR), and controlled attenuation parameter (CAP); aspartate aminotransferase (AST) was retained for robustness. This evidence concerns the gene GPT and Insulin resistance.